“…In the EIP model studies herein, statin use reduced neutrophil count and activity, the expression level of various proinflammatory cytokines (e.g., interleukin [IL]‐1, IL‐6, IL‐8, tumor necrosis factor‐α) and various enzymes (e.g., cyclooxygenase‐2, inducible isoform of nitric oxide synthase and matrix metalloproteinases 1, 2, 8, 9) affecting inflammatory pathways and tissue and bone remodeling, and oxidative stress, while it increased the levels of the anti‐inflammatory cytokine, IL‐10, and osteoprotegerin, expression of bone morphogenetic protein‐2 and vascular endothelial growth factor immunoreactivity . The combined effect of reduced anti‐inflammatory response — regularly associated with reduced degradation of soft and hard tissue — and of enhanced wound‐healing potential during periodontal disease, thus explains the significantly higher alveolar bone level/amount and/or attachment level compared with controls, observed in 81% and 100%, respectively, of the EIP model studies included.…”